







## AUTHOR CORRECTION OPEN



# Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

Lorna Hopcroft , Eleanor M. Wigmore, Stuart C. Williamson , Susana Ros , Cath Eberlein, Jennifer I. Moss, Jelena Urosevic, Larissa S. Carnevalli , Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J. A. Goodwin, Brandon S. Willis, Claire Rooney, Elza DeBruin  and Simon T. Barry 

*npj Breast Cancer* (2023)9:69; <https://doi.org/10.1038/s41523-023-00575-6>

Correction to: *npj Breast Cancer* <https://doi.org/10.1038/s41523-023-00571-w>, published online 05 August 2023

In this article the author name Scott Hoffmann, was incorrectly written as Scott Hoffman. The original article has been corrected.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

Published online: 18 August 2023

Published in partnership with the Breast Cancer Research Foundation

npj

BCRF  
BREAST  
CANCER  
RESEARCH  
FOUNDATION